Breakthrough cancer diagnostics. Next-level clinical outcomes.
Foresight Diagnostics develops and delivers innovative diagnostic tests that combine precision genomics and cutting-edge bioinformatics to advance cancer drug development and patient care.
Actionable data when it matters most
Uncover residual disease at key landmarks throughout the patient treatment journey with Foresight CLARITY™, our ultra-sensitive MRD platform powered by PhasED-Seq™ technology.
Unparalleled access
to experts
Foresight offers thought leaders and experts spanning liquid biopsy, clinical, regulatory, and operations to develop, execute, and accelerate your clinical programs and studies.
Proven and trusted ultra-sensitive performance
Our patented technology identifies and tracks patient- and tumor-specific phased variants (PVs). Peer-reviewed evidence showcases circulating tumor DNA (ctDNA) detection across multiple cancer types below the limits of detection of conventional methods.
CLARITY in action
With more than 30 publications and over 25 academic and biopharma partners, Foresight and our collaborators are paving the way for new possibilities in oncology care through clinical research and drug development.
From using minimal residual disease (MRD) as an enrollment biomarker to accelerating trials with MRD as an endpoint, our partners are at the forefront of cancer research with Foresight CLARITY™.
